Enzo Biochem, Inc. (ENZ) CEO Elazar Rabbani Sells 14,000 Shares

Enzo Biochem, Inc. (NYSE:ENZ) CEO Elazar Rabbani sold 14,000 shares of the business’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $7.75, for a total value of $108,500.00. Following the completion of the transaction, the chief executive officer now directly owns 1,867,202 shares of the company’s stock, valued at approximately $14,470,815.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Elazar Rabbani also recently made the following trade(s):

  • On Wednesday, October 25th, Elazar Rabbani sold 72,401 shares of Enzo Biochem stock. The shares were sold at an average price of $10.09, for a total value of $730,526.09.

Enzo Biochem, Inc. (ENZ) traded up $0.17 during mid-day trading on Friday, reaching $7.96. The company had a trading volume of 147,953 shares, compared to its average volume of 192,438. The firm has a market capitalization of $373.06, a P/E ratio of -199.00 and a beta of 0.87. Enzo Biochem, Inc. has a fifty-two week low of $6.27 and a fifty-two week high of $12.04.

Enzo Biochem (NYSE:ENZ) last posted its quarterly earnings results on Thursday, December 7th. The medical research company reported ($0.01) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.01). The business had revenue of $27.68 million during the quarter, compared to the consensus estimate of $27.51 million. Enzo Biochem had a negative return on equity of 1.89% and a negative net margin of 1.53%. analysts predict that Enzo Biochem, Inc. will post -0.02 EPS for the current fiscal year.

Separately, TheStreet downgraded Enzo Biochem from a “b” rating to a “c+” rating in a research note on Wednesday, September 27th.

Hedge funds have recently bought and sold shares of the stock. Legal & General Group Plc raised its stake in Enzo Biochem by 10.6% during the second quarter. Legal & General Group Plc now owns 10,663 shares of the medical research company’s stock worth $119,000 after acquiring an additional 1,022 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Enzo Biochem during the second quarter worth about $124,000. CAPROCK Group Inc. acquired a new position in Enzo Biochem during the third quarter worth about $118,000. Magnetar Financial LLC acquired a new position in Enzo Biochem during the third quarter worth about $121,000. Finally, LMR Partners LLP acquired a new position in Enzo Biochem during the third quarter worth about $149,000. 63.65% of the stock is owned by institutional investors and hedge funds.

WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/19/enzo-biochem-inc-enz-ceo-elazar-rabbani-sells-14000-shares.html.

About Enzo Biochem

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply